1Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, CT
2University of California, San Francisco, CA
3East Bay Physicians Medical Group, Berkeley, CA
4Pfizer Inc, New York, NY
5Pfizer Inc, Groton, CT
6Pfizer Ltd, Tadworth, Surrey, UK.
Address correspondence to: Hugh S. Taylor, MD, Anita O’Keeffe Young Professor and Chair, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, 333 Cedar Street, New Haven, CT 06520. E-mail: [email protected]
Received 14 December, 2015
Revised 10 May, 2016
Accepted 10 May, 2016
Funding/support: Bruce Ettinger, MD, provided early consultation, including assistance with development of the survey. Medical writing support was provided by Lauren Cerruto and Diane M. Sloan, PharmD, of Peloton Advantage and was funded by Pfizer Inc. This survey was sponsored by Pfizer Inc.
Financial disclosure/conflicts of interest: H.S.T. has served as a consultant to AbbVie, Bayer, OvaScience, and Pfizer, and has received grants (to Yale University) for research support. R.K. has served as a consultant/advisory board member for Amgen, Foundation for Osteoporosis Research and Education/American Bone Health, Merck & Co, Noven Pharmaceuticals, Novo Nordisk A/S, Own the Bone Advisory Board of the American Orthopedic Association, Pfizer, Shionogi, Sprout, and TherapeuticsMD; has received grants/research support (fees to Institution) from TherapeuticsMD; has served on a speaker's bureau for Novo Nordisk A/S, Shionogi, Noven Pharmaceuticals, and Pfizer; and has received editorial writing support from Pfizer. C.J.A. and S.C. were employees of Pfizer at the time the survey was conducted. A.G.B. and L.A. are employees of Pfizer.
